China Resource Sanjiu Medical & Pharmaceutical Co., Ltd. ("CR Sanjiu" for short) is a large-scale state-owned listed medicine company, formerly known as Shenzhen South Pharmaceutical Company. On March 9, 2000, it got listed in Shenzhen Stock Exchange, with Stock Code 000999.

The company is mainly engaged in R&D, manufacture and sale of medical and pharmaceutical products and the relevant health services. It has four pharmaceutical business modules of OTC, Chinese medicine prescription drugs, free-decocted traditional Chinese medicine, antibiotics & generic drugs, supplemented by such relevant business as packaging & printing, medical services etc. In 2005, the "999" brand value was 8.306 billion Yuan. According to the ranking list of "China's 100 Most Valuable Famous Brands" issued by Chinese Brand Institute, the "999" brand ranked the first in pharmaceutical industry. The company has over 10 manufacturing enterprises throughout the whole country which have had Chinese and international GMP certification, and the product dosage forms cover all the common ones, for example, capsule, tablet, oral liquid, granule and injection. In 2008, the company achieved the main business income of 4.316 billion Yuan. The company's 999 brand products have relatively high occupancy and popularity in the national pharmaceutical market. Core products of the company: Sanjiu Wei Tai, 999 Ganmaoling, 999 Pi Yan Ping, Zhengtian Pills, Shenfu Injection, Xin Tai Lin (cefazolin sodium pentahydrate vial), etc., with annual sales of single variety beyond 100 million RMB. Among them, sale of 999 Ganmaoling series in 2008 was beyond 800 million Yuan, the first in the cold cure (including Western medicine) market; Annual sale of 999 Pi Yan Ping was nearly 500 million Yuan.

Shenzhen 999 Chinese Medicine Investment & Development Co., Ltd., the key wholly-owned member enterprise subordinated to CR Sanjiu, which is fully responsible to manage the sales of "999" brand health products of CR Sanjiu in the oversea market, carries out the investment and management of the subsidiary companies and Chinese medical clinics established in the oversea market, and provides support and management for the oversea agents of "999" brand health products.